Essential Thrombocythemia — Trials

Essential Thrombocythemia — Trials · CancerIndex

Clinical trials

Registered studies

93 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 24
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07612280	Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	recruiting	Phase 1 / Phase 2	30	Jubilant Therapeutics Inc.INDUSTRY	1	Jun 3, 2026	clinicaltrials
NCT05123365	An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms	recruiting	Phase 1 / Phase 2	27	University of California, IrvineOTHER	1	Mar 10, 2026